Latest ZORA Findings Support Efficacy of SZC

Three presentations at the 61st European Renal Association (ERA) Congress focused on results from the ZORA study. All demonstrated the positive impact of renin-angiotensin-aldosterone system inhibitor (RAASi) therapy when paired with the potassium binder LOKELMA (sodium zirconium cyclosilicate, or SZC).

The findings presented at ERA showed (1) at 6 months, patients on SZC were more likely to stay on RAASi, (2) those who stayed on SZC for 30+ days were more likely to stay on RAASi, (3) staying on RAASi is associated with lower risk for hospitalization.

Anjay Rastogi, MD, PhD, clinical chief of nephrology at UCLA Health and co-author of two of the ZORA analyses, spoke with Nephrology Times about the findings.

CORRECTION: At 2:21, the statistic regarding data presented at ASN Kidney Week 2023 is incorrect. Discontinuation of RAASi therapy led to a 73% increase in end-stage kidney disease, not 76%.